Earlier this year we covered Biogen’s decision to file Aducanumab (their experimental treatment for Alzheimer’s Disease) here and here.
This saga reignited this past week with the publication of FDA adcom documents which on the surface looked positive sending the shares soaring only to be voted down (8-1) at the meeting on Friday sending them crashing down.
This really good blog post discusses these events and why it is always important to read all the details.
The final FDA outcome is yet to be determined (Adcom decisions aren’t binding) and as previously highlighted could be political.
